Design and development of microemulsion drug delivery system of atorvastatin and study its intestinal permeability in rats by Mandal, Surjyanarayan et al.
International Journal of Drug Delivery 2 (2010) 69-75 
http://www.arjournals.org/ijdd.html 
 
 Research article  ISSN: 0975-0215 
 
Design and development of microemulsion drug delivery system of 
atorvastatin and study its intestinal permeability in rats 
 
 Surjyanarayan Mandal1*, Snigdha S. Mandal1, Krutika K. Sawant2 
 
*Corresponding author: 
Surjyanarayan Mandal 
1Dept. of  Pharmacy, Baroda 
College of Pharmacy, PASM, 
Limda,  
Vadodara, Gujarat 391760. 
Phone: 02668-263355/56 
Tele Fax: 02668-262327 
E-mail: 
surjya05n08@gmail.com 
 
2Professor, Department of 
Pharmaceutics  
TIFACORE, MSU, Donors 
Plaza, Opp. University Main 
Office, The M. S. University 
of  Baroda,  
Vadodara, Gujarat 390 002,  
India. 
Email: 
dr_krutikasawant@yahoo.co.
in 
 
 
 
 
 
 
 
 
 
Abstract: 
The objective of this study was to design and develop microemulsion drug 
delivery system of Atorvastatin and to investigate its intestinal transport 
behavior using the single-pass intestinal perfusion method in rat. 
Microemulsion drug delivery system of Atorvastatin was prepared by water 
titration method and optimized formulation was characterized. The 
permeability behavior of Atorvastatin over three different concentrations (10, 
20 and 40 μg/mL) was studied in each isolated region of intestine (i.e. 
duodenum, jejunum, ileum and colon) of rat by single-pass intestinal 
perfusion method in rat method at a flow rate of 0.2 ml/min. The 
concentration of the sample was determined by HPLC and the effective 
permeability coefficients were calculated. Considering the high correlation of 
rat permeability coefficient values with those of human, the human intestinal 
permeability was predicted using the Lawrence compartment absorption and 
transit model. The intestinal permeability of Atorvastatin in microemulsion, 
plain drug suspension and marketed formulation was also compared. The 
particle size and zeta potential of Atorvastatin microemulsion were 
(18.2±0.3) nm and (–9.19±0.8) mV respectively. There was no significant 
difference in permeability coefficient in jejunum, duodenum and ileum with 
same concentration but higher in colon was observed. The permeability 
coefficient in jejunum at 10 μg/mL was significantly higher than that at 40 
μg/mL (p< 0.01). The estimated human intestinal permeability of 
Atorvastatin for the microemulsion was relatively higher. Based on the above 
results, it could be concluded that microemulsion formulation could enhance 
the intestinal permeability of Atorvastatin and thus could be presented as a 
possible alternative to traditional oral formulations for improving the oral 
absorption of Atorvastatin. 
 
Keywords: Microemulsion;, Zeta potential; Atorvastatin; Single-pass 
intestinal perfusion (SPIP) method; Compartment absorption and transit 
model (CAT) 
 
Introduction  
In recent years, much attention has been focused on 
using  microemulsion   drug   delivery   system  for  the  
 
purpose of improving the solubility and oral absorption 
of poorly water-soluble drugs [1-5]. Microemulsion 
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system, an isotropic mixture of oil, surfactant and co-
surfactant along with water is optically clear and 
thermodynamically stable system with a droplet size in 
a range of 10-100 nm. This system has been shown to 
improve absorption of drugs due to small droplet size 
and promotes intestinal lymphatic transport due to its 
specific components [6]. Atorvastatin, a semi synthetic 
hypolipidemic drug, selectively and competitively 
inhibits 3-hydroxy-3-methylglutaryl-coenzyme-A 
reductase (HMG-CoA reductase) catalyzes the 
conversion of HMG-CoA to mevalonate, which is 
required for cholesterol biosynthesis. Atorvastatin is a 
poor water-soluble drug and has a very low absolute 
bioavailability (about 5%) due to rapid metabolism in 
the gut and liver [7]. Since Intestinal permeability is 
necessary for oral administration so in this study, 
microemulsion drug delivery system was developed to 
improve the solubility and oral absorption of 
Atorvastatin. Labrafil M 1944CS, Cremophor RH 40 
and ethanol were used as oil phase, surfactant and co-
surfactant respectively. The intestinal permeability of 
Atorvastatin was determined using the single pass 
intestinal perfusion (SPIP) in rats since this method 
provides a unique advantages of experimental control 
(e.g. compound concentration and intestinal perfusion 
rate), ability to study regional differences and an intact 
intestinal blood supply and a functional intestinal 
barrier [8]. 
 
Materials and Methods 
Materials  
Atorvastatin was obtained from Torrent Research 
Center (Ahmedabad, India). Capmul MCM, Labrafac 
CC, Cremophor EL, Cremophor RH 40, Labrafil M 
1944CS and Transcutol P were kindly provided by 
Gattefosse, france.  Isopropyl Myristate (IPM), Tween 
60, PEG 600, PEG 400, Ethanol, Glycerol, Ammonium 
acetate, Sodium citrate, Acetonitrile (HPLC grade) and 
Methanol (HPLC grade) were purchased from National 
Chemicals (Baroda, India). All other Chemicals were 
reagent grade. 
 
Animals 
Male Albino rats (250 ± 20 g) were used for the 
comparative in vivo studies. The animals were 
maintained at temperature (25±1°C), and humidity 
(60±5%) and were supplied with food and water ad 
libitum. Animal experiments were approved by Social 
Justice and Empowerment Committee, Ministry of 
Government of India, New Delhi, India, with the 
permission number of 404/01/a/CPCSEA. The protocol 
was approved by Local Animal Ethics Committee. 
Male albino rats were obtained from Zydus Health 
care, Ahmadabad, India.  
 
Solubility Studies 
The solubility of atorvastatin in various oils (Sunflower 
oil, Isopropyl Myristate, soya bean oil, Labrafil M 
1944CS, Capmul CMC), surfactant (Labrafac CC, 
Tween 60, Cremophor EL, Cremophor RH 40), and 
cosurfactants (PEG 400, PEG 600, glycerol, ethanol) 
was determined. A total of 2 mL of each of the selected 
vehicle were added to each cap vial containing 100mg 
of Atorvastatin. After sealing, the mixture was heated 
at 40°C in a water bath to facilitate the solubilization 
and then mixed using a vortex mixer. Mixtures were 
then shaken with mechanical shaker at 25°C for 48 hrs. 
Then each vial was centrifuged at 8000 rpm for 15 min, 
and insoluble as well as soluble Atorvastatin was 
quantified by UV spectroscopy [9]. Table 1 shows the 
results of the solubility studies. 
 
Table 1: Solubility studies data of Atorvastatin in 
different vehicles 
 
S. No. Vehicles Solubility 
(mg/ml±SD) 
1 Sunflower oil 24.9 ± 2.2 
2 Isopropyl Myristate 34.9 ± 1.8 
3 Soya bean oil, 20.1 ± 1.1 
4 Labrafil M 1944CS 57.7 ± 1.3 
5 Capmul CMC 8.4 ± 1.2 
6 Labrafac CC 26.5 ± 2.7 
7 Tween 60 5.56 ± 0.9 
8 Cremophor EL 11.4 ± 1.2 
9 Cremophor RH 40 28.2 ± 1.1 
 
Pseudo-ternary Phase Diagram Study 
Pseudo-ternary phase diagrams of microemulsion were 
to obtain the optimum concentration of oil, surfactant 
and co-surfactant. After performing the solubility study 
and phase diagram study, components were selected for 
microemulsion formulation. The effect of Atorvastatin 
in the phase diagrams was also investigated [10].  
 
Preparation of Atorvastatin microemulsion system 
Atorvastatin containing microemulsion was prepared 
by water titration method [11]. Atorvastatin was first 
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dissolved in the pre-measured volume of oil by stirring 
on a magnetic stirrer. A mixture of the surfactant and 
co-surfactant at a fixed ratio (v/v) was added to the 
above resulting mixture. Finally this mixture was 
titrated with distilled water. The optimized 
microemulsion drug delivery system was also subjected 
for accelerated stability study. 
 
Particle size and zeta potential measurement 
Particle size and zeta potential of Atorvastatin 
containing microemulsion drug delivery system was 
carried out by dynamic light scattering through with 
Zetasizer 3000HS, Malvern Instruments Corporation, 
U.K. Drug loaded microemulsion was also assayed for 
% drug content.   
 
Single-pass intestinal perfusion (SPIP) of the rat 
segments 
Before the SPIP experiment, sufficient Krebs-Ringer’s 
buffer solution was added to adjust the formulations to 
a designed concentration. The intestinal permeability 
experiments of the microemulsion formulation with 
different concentrations of the Atorvastatin were 
investigated and compared to both PDS and MFA of 
equivalent drug concentration. Preliminary studies are 
necessary before commencing the SPIP studies to 
ensure that the loss of drug from perfusion is due to 
absorption and not by other losses (e.g. the binding of 
the intestinal wall or degradation) [12]. Approximately 
10 cm from the rat intestine was clipped, intestinal sac 
were turned over and put into 50 mL Krebs-Ringer’s 
buffer solution, in which Atorvastatin (20μg/mL) was 
incubated at 37±2°C for 3 Hrs. Samples of 40μl were 
withdrawn at 3 Hrs interval, diluted with acetonitrile, 
methanol and water (mobile phase-4.5:4.5:1) and 
assayed by HPLC. SPIP studies were performed 
according to previously described methods [13, 15]. 
After an overnight fast, male albino rats (weighing 
approximately 250 ± 20 g) were anesthetized with an 
i.p. injection of 20% (w/v) urethane solution (urethane: 
1g/kg). A surgical lamp was kept under the rat’s cage 
to maintain the body temperature. The abdomen was 
opened with a midline incision, an intestinal segment 
of approximately 10 cm was chosen and separated. 
Intestinal segment was then rinsed with isotonic saline 
(37°C) until the outlet solution was clear. Using an 
infusion pump the intestinal segments were perfused at 
a flow rate of 0.2 ml/min for 30 min with Krebs-
Ringer’s buffer solution. Then the pump was connected 
to the reservoir containing Atorvastatin loaded 
microemulsion system with the Phenol Red (Marker). 
Setting t=0 when the buffer solution has been 
completely pushed out. Each perfusion experiment 
lasted for 180 min. and the perfusate was quantitatively 
collected in 60, 75, 90, 105, 120, 135, 150, 165 and 180 
min. Samples were stored in a refrigerator at 4°C until 
analysis by HPLC. 
 
HPLC analysis of samples 
All samples were diluted to 5 ml with the mobile phase 
and measured by HPLC (Shimadzu, Japan) system 
consisting of membrane degasser, binary solvent 
delivery system, a pump, a rheodyne injector equipped 
with a 20 μl sample loop and UV detector (Shimadzu, 
Japan) [16]. Aliquots of 20 μl were injected onto the 
HPLC system, was used to analyze Atorvastatin at 332 
nm. Chromatographic separations were achieved using 
an Hypersil ODS C18 column (250×4.6 i.d.×5 µm). 
The mobile phase used for the sample analysis was 
Acetonitrile, methanol and water of HPLC grade 
(45:45:10 V/V) with the flow rate of 1.0 ml/min.  
 
Table 2. Data of optimized microemulsion 
 
Characterization Particle 
size (nm) 
Zeta 
Potential 
(mV) 
Poly 
dispersibilit
y Index 
(PDI) 
% 
Drug 
Conten
t 
Atorvastatin ME 18.2±0.3 –9.19±0.8 0.281 98.72±1
.87 
 
 
Water absorption or secretion (flux) was measured by 
gravimetric method [17-18]. The net water flux (NWF) 
per cm of each segment was calculated using the 
following equation and results were tabulated in Table 
3: 
 
 NWF (μl/min/cm) = [(1-CPRout / CPRin)×Qin /L]×1000. 
 
Where, CPRin and CPRout were the inlet and outlet 
concentration of phenol red, respectively. Qin was the 
flow rate of the perfusion solution entering the 
intestinal segment and L was the length of the intestinal 
segment (cm).  If Intestinal lumen absorbs water NWF 
will be negative and if intestinal lumen secretes water 
NWF is positive value, however under normal 
condition, intestinal lumen absorbs water except when 
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the high osmotic solution is administered [19]. The 
effective permeability (Peff) was calculated based on the 
inlet and outlet concentration of Atorvastatin (Cin and 
Cout, respectively) and result was shown in Figure 1. 
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Figure 1. Plot of the concentration ratio of Cout/Cin 
V/s Time. 
 
 
Steady state was considered to have been achieved 
when the concentration of phenol red and Atorvastatin 
were constant. The permeability values are calculated 
after steady state was achieved using the following 
equation [20]: 
 
  Peff = [Q ln (Cin / Cout)′ ]/ 2π rL 
                     
Where Q is the flow rate in mL/min, r is radius of the 
intestine (0.18 cm in rat and 1.75 cm in man), L is the 
length of the perfused intestinal segment (cm), and 
(Cin/Cout)′ is the concentration ratio corrected for fluid 
flux. Using ANOVA, the statistical significance of the 
differences among group means were assessed with the 
least significant difference (LSD) test and a value of 
p<0.05 was considered statistically significance. 
 
Results 
Microemulsion drug delivery system formulations 
Labrafil M 1944CS was selected as the oil phase for 
formulation development because it provided higher 
solubility than other oils and oral compatibility. 
Cremophor RH 40 as surfactant and ethanol as co-
surfactant were used on the basis of their drug 
solubilising capacity and might influence the tight 
junctions of the epithelial cells. From the results of the 
pseudo-ternary phase diagram, 3:1 ratio of Cremophor 
RH 40 and ethanol was selected for microemulsion 
preparation. The optimal formulation of microemulsion 
drug delivery system was 3% oil, 27.75% surfactant, 
9.25% co-surfactant and 60% as aqueous phase. 
Moreover Atorvastatin microemulsion drug delivery 
systems were stable for 6 months at ambient 
temperature. 
 
Particle sizes and zeta potential measurement 
Particle size, zeta potential and % drug content of 
Atorvastatin microemulsion were tabulated in Table 2.   
 
Validation of HPLC assay 
The regression equation for the concentration of 
Atorvastatin (ng/ml) V/s response in the perfusion fluid 
ranging from 50 ng/ml to 500 ng/ml was A = 
93.21C+620.3 (R2 = 0.9998). The mean recovery of 
Atorvastatin was 100.8±1.31%. The intra-day and 
inter-day RSDs were less than 2%.  
 
Table 3: The net water flux (NWF) in each 
intestinal segment (n=4) 
 
 Time   
 (min) 
Duodenum Jejunum Ileum Colon 
70 -0.584±0.121 -0.144±0.175 -0.102±0.056 -0.129±0.018
90 -0.555±0.212 -0.117±0.128 -0.238±0.078 -0.197±0.056
110 -0.789±0.374 -0.209±0.124 -0.237±0.032 -0.426±0.244
130 -0.672±0.221 -0.206±0.226 -0.345±0.057 -0.298±0.057
 
Water absorption or secretion of intestinal lumens 
The NWF for all intestinal segments were negative 
value as listed in Table 3, which suggested that the 
water was mainly absorbed in the intestine tract. The 
NWF for the duodenum was significantly higher than 
that for the jejunum, ileum and colon (P<0.05) and 
NWF for the jejunum, ileum and colon were not 
significantly varied (P>0.05). 
 
SPIP studies 
The amount of Atorvastatin remained after incubated in 
the Krebs-Ringer’s buffer with the intestinal sac for 3 
hrs was 99.32 ± 1.23%, which was not significantly 
decreased which suggested that neither Atorvastatin 
markedly bind to the intestinal wall nor the potential 
metabolites were formed. The intestinal permeability of 
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Atorvastatin was studied as a function of concentration 
in each segment of the intestine and 40 μg/ml 
concentration was chosen because of its limited 
aqueous solubility. Steady state is confirmed by 
plotting the concentration of Atorvastatin and phenol 
red versus time in Figure 1. Steady state, which was 
assessed by the constant concentrations of both phenol 
red and Atorvastatin, was reached about 50 min after 
the beginning of the perfusion. The permeability values 
were calculated only after steady state was achieved in 
the experiments. The permeability values of 
microemulsion drug delivery system for each intestinal 
segment and concentrations are listed in Table 4. Peff in 
the jejunum at 10 μg/mL (0.388±0.021 cm/s) was 
significantly higher than Peff at 40 μg/mL (0.229±0.037 
cm/s, p<0.01). There was no statistical difference in Peff 
at three investigated concentrations in other segments 
(including duodenum, ileum and colon). Comparisons 
across each segment revealed that Peff at each 
concentration in colon was higher than all other 
segments (p<0.01). Moreover, the permeability values 
in duodenum, jejunum and ileum were not statistically 
different (p>0.05).  
 
 
Table-4: Comparison of effective permeation 
coefficients (Peff ×10-4) of different intestinal 
segments with three concentrations. Results are 
given as mean ± S.D (n=4). 
 
 
Conc. of 
Atorvasta
tin 
(μg /mL) 
Peff (cm/s) 
 in Duodenum 
Peff (cm/s) 
 in Jejunum 
Peff (cm/s)  
in Ileum 
Peff (cm/s) 
 in Colon 
10 0.435±0.049 0.445±0.026 0.475±0.052 0.625±0.096 
20 0.402±0.045 0.414±0.042 0.456±0.067 0.598±0.085 
40 0.401±0.068 0.377±0.057 0.437±0.116 0.532±0.068 
 
Permeability values of Atorvastatin in the formulation 
of microemulsion drug delivery system, PDS and MFA 
for each segment at 10 μg/mL were shown in Figure-2. 
Peff of microemulsion drug delivery system was 
significantly higher than PDS and MFA in each 
segment (p<0.01). Except the duodenum (p<0.05), Peff 
of microemulsion drug delivery system and MFA in the 
jejunum, ileum and colon did not all reach statistical 
difference (p>0.05). 
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Figure 2. Comparison of Peff of the ME, PDS and 
MFA in different intestinal segments (n=4) at 
concentration of the Atorvastatin as 10 μg/mL. 
 
Discussions  
Peff in the colon at each concentration was significantly 
higher than those in other segments of rat intestine as 
shown in Table 3. There are various reports showing 
the regional difference in the expression and activity of 
P-glycoprotein throughout the gastric intestinal tract 
[21]. The order of the expression and activity of P-
glycoprotein is ileum> duodenum and jejunum> 
proximal and distal colon [22]. As a multi-drug 
resistance-reversing agent, the intestinal absorption of 
Atorvastatin was limited due to the presence of the P-
glycoprotein throughout the intestinal tract [23]. The 
lower expression activity of P-glycoprotein conduced 
to be increasing the permeability of Atorvastatin in 
colon as compared to other sections (Table 3). It has 
been shown that there is a selectivity of permeation 
depending of the gut sections. Moreover, small 
intestine has more cationic selectivity, whereas, the 
colon has more anionic selectivity [24]. Another 
possible mechanism for higher Peff values in colon was 
due to the higher crypt surface area in the colonic 
mucosa compared with the small intestine which could 
account for its high paracellular permeability [25]. The 
extent of drug absorption in human can be predicted 
from rat intestinal permeability experiments. Human 
intestinal permeability values may be estimated using 
the Lawrence compartmental absorption and transit 
(CAT) model [26]:  
 
Fa (fraction of dose absorbed) =1-[1+ 0.54 Peff (man)]-7   
P eff (man) = 3.6×Peff (rat) + 0.03×10-4  
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The estimated Fa for Atorvastatin in the microemulsion 
system, MFA and PDS were 85.5±1.9% 59.3±3.1% 
and 81.2±2.2%, respectively. It suggested that the 
estimated oral absorption in human for microemulsion 
drug delivery systems would be higher than that for 
PDS and MFA (p<0.01). Microemulsion drug delivery 
system is known to improve the oral absorption of 
lipophilic drugs. The main mechanism reported include 
increasing membrane fluidity, opening tight junction, 
inhibiting P-gp and/or CYP450 by surfactants and 
stimulating lipoprotein/chylomicron production by 
lipid.  
 
Conclusions 
According to these results, several conclusions can be 
drawn. The Atorvastatin microemulsion drug delivery 
system had a small particle size (28.6±0.3 nm) and a 
native charge. Atorvastatin microemulsion drug 
delivery system and its dilutions were stable. The Peff in 
jejunum at 10 μg/mL were significantly higher than 
that at 40 μg/mL (p< 0.01). Compared to the jejunum, 
duodenum and ileum, the higher Peff in colon were 
observed at the same concentration. The estimated 
absorption of Atorvastatin in human for the 
microemulsion drug delivery system was higher than 
that for PDS and MFA (p<0.01).  
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